H3K27 methylation is a chemical tag placed on a specific amino acid of histone H3, one of the proteins that DNA wraps around inside the nucleus. When a Polycomb protein complex adds methyl groups to this position, the surrounding genes tend to shut down. This mark is central to how cells decide which genes to keep off during embryonic development, how tissues maintain their identity throughout life, and how things go wrong in certain cancers and developmental syndromes. The biology around this single histone modification turns out to be surprisingly layered, with different degrees of methylation doing different jobs, and with removal of the mark being just as important as its placement.
How the Mark Gets Placed
The enzyme complex responsible for H3K27 methylation is called Polycomb Repressive Complex 2, or PRC2. It adds methyl groups to the lysine at position 27 on histone H3, and this modification is strongly linked to gene silencing.1PubMed Central. Structure, mechanism, and regulation of polycomb-repressive complex 2 PRC2 is built from several core subunits. The catalytic piece, called EZH2, contains the enzymatic domain that actually transfers the methyl groups. But EZH2 cannot work alone. It needs a partner called EED that recognizes the existing trimethyl mark on nearby histones and feeds that information back into the complex, boosting its activity. A third subunit, SUZ12, bridges the other two and helps stabilize the whole assembly. Crystal structures of this complex show that EED sits within a belt-like embrace of EZH2, and the catalytic site is split in an unusual way that only becomes functional when all subunits are properly assembled.2PubMed Central. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2
This built-in feedback loop matters for how the mark spreads along a chromosome. When PRC2 encounters a histone that already carries the trimethyl tag, EED binds that mark and allosterically stimulates EZH2, encouraging it to methylate the next histone over. The result is that PRC2 can coat a stretch of chromatin with repressive marks, creating broad silenced domains. That spreading behavior is key to understanding both normal gene regulation and what happens when PRC2 goes haywire.
Three Levels of Methylation, Three Different Jobs
Lysine 27 on histone H3 can carry one, two, or three methyl groups, referred to as H3K27me1, H3K27me2, and H3K27me3. These are not simply steps on a ladder toward full silencing. Each form occupies different parts of the genome and is associated with distinct sets of genes. In embryonic stem cells, roughly 27% of the trimethyl mark (H3K27me3) peaks sit at gene promoters, compared with about 8% for the dimethyl form (H3K27me2). H3K27me3 concentrates tightly around the start sites of genes involved in cell fate commitment and neural differentiation, and the majority of those genes are either silent or barely active. By contrast, H3K27me2 covers a broader swath of the genome and is found at genes that are more actively transcribed, particularly those tied to metabolic processes.3Cell Reports. Roles of H3K27me2 and H3K27me3 Examined during Fate Specification of Embryonic Stem Cells
The dimethyl form appears to serve a protective function. When PRC2 is active, H3K27me2 blankets large stretches of chromatin outside the heavily silenced domains, preventing those regions from picking up acetylation marks that would activate enhancers at the wrong time. Lose PRC2 activity, and new acetylation peaks appear at sites that had been covered by H3K27me2, potentially switching on enhancers that should stay dormant in that cell type.4Molecular Cell. PRC2 Activity Regulates Genomic Domains of H3K27 Methylation, Activating Transcription and Prevent Enhancer Firing So while H3K27me3 gets most of the attention as the “silencing mark,” the dimethyl form quietly guards the rest of the genome from unauthorized activation.
Bivalent Domains and Developmental Poising
One of the more striking discoveries in chromatin biology is that certain gene promoters in stem cells carry both a silencing mark (H3K27me3) and an activating mark (H3K4me3) at the same time. These are called bivalent domains. The idea is that lineage-control genes are kept silent by the H3K27me3 mark while simultaneously being “poised” for rapid activation by H3K4me3.5PubMed Central. Generation of bivalent chromatin domains during cell fate decisions When a stem cell receives a signal to differentiate into a particular cell type, the repressive mark is stripped from the relevant genes while the activating mark stays, and transcription ramps up quickly. Genes destined for other lineages keep their repressive marks and stay off.
This pattern has been documented in embryonic stem cells, zebrafish embryos, and other contexts.6PubMed Central. Bivalent histone modifications in early embryogenesis It provides a neat explanation for how a single cell type can maintain the potential to become many things: the genes for each possible fate are silenced but primed for activation. Once a fate decision is made, the bivalent state resolves in one direction or the other.
The Acetylation Rivalry at Position 27
H3K27 can be either methylated or acetylated, but not both at the same time. Acetylation at this position (H3K27ac) is a hallmark of active enhancers and gene promoters, so the two modifications are in direct competition. When PRC2 is inactivated and H3K27 methylation drops, acetylation tends to flood in. This switch has been observed genome-wide when the EED subunit of PRC2 is knocked out in stem cells, leading to new H3K27ac peaks at sites that were previously methylated.4Molecular Cell. PRC2 Activity Regulates Genomic Domains of H3K27 Methylation, Activating Transcription and Prevent Enhancer Firing
However, acetylation at this site is not always required for genes to become active. Histone-editing experiments have shown that H3K27 acetylation is dispensable for gene derepression when H3K27 methylation is lost, and also dispensable during certain cell-fate transitions.7Nature Genetics. Histone editing elucidates the functional roles of H3K27 methylation and acetylation in mammals In other words, removing the silencing mark may be enough on its own, without requiring the activating mark to replace it. The acetylation that commonly appears after demethylation might be a consequence of gene activation rather than a cause.
Removing the Mark
If H3K27 methylation were permanent, cells would never be able to turn silenced genes back on. In practice, dedicated demethylase enzymes from the KDM6 family (UTX and JMJD3) strip methyl groups from H3K27me3. But the story is not as simple as “PRC2 puts it on, KDM6 takes it off.” Embryonic stem cells engineered to lack all KDM6 demethylase activity still manage to lose H3K27me3 from key developmental gene promoters during differentiation. Hox gene promoters, for example, shed their H3K27me3 and gain H3K4me3 on schedule even without active demethylation, and gene expression proceeds normally.8PubMed Central. KDM6 Demethylase Independent Loss of Histone H3 Lysine 27 Trimethylation during Early Embryonic Development
This finding suggests that early embryonic cells can dilute the mark passively through DNA replication, simply by not re-establishing it on newly assembled histones during cell division. Active erasure by demethylases becomes more important in later, non-dividing, or slowly dividing cells where passive dilution is not an option.
Development, Hox Genes, and Imprinting
PRC2 and H3K27me3 are perhaps most famous for their role in regulating Hox genes, the master switches that assign identity to different segments of the body along the head-to-tail axis. In developing limbs, PRC2 restricts the physical interactions between certain Hox gene clusters and their distant enhancers. When PRC2 is present in the proximal part of a limb, it confines the HoxA cluster so that genes like Hoxa13, which specify distal (finger-tip) identity, stay silent where they do not belong.9Developmental Cell. PRC2 Has a Dual Role in Region-Specific HoxA Gene Regulation and 3D Chromatin Organization PRC2’s influence here goes beyond simply silencing genes: it shapes the three-dimensional folding of chromatin to keep enhancers away from the wrong promoters.
H3K27me3 also turns up in a less intuitive context: genomic imprinting. Normally we think of DNA methylation as the mechanism that silences one parental copy of an imprinted gene. But maternal H3K27me3 can independently silence specific genes inherited from the mother, including genes involved in X chromosome inactivation. In mice, maternal H3K27me3 represses the Xist gene on the maternal X chromosome, ensuring that the paternal X is the one that gets inactivated in early female embryos.10PubMed Central. Maternal H3K27me3-dependent autosomal and X chromosome imprinting
When H3K27 Methylation Goes Wrong in Cancer
Cancers have found multiple ways to exploit or disrupt the H3K27 methylation system. Some cancers gain too much of the mark, silencing tumor suppressor genes that should be active. Others lose it, unleashing genes that drive uncontrolled growth. Which direction the disruption goes depends on the tumor type.
In certain B-cell lymphomas, the EZH2 gene itself picks up activating mutations. A recurrent mutation at a single tyrosine residue (Tyr641) in the catalytic domain shows up in about 22% of germinal-center diffuse large B-cell lymphomas and about 7% of follicular lymphomas.11PubMed Central. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin These mutations increase the enzyme’s ability to convert H3K27me2 to H3K27me3, flooding the genome with the trimethyl mark and over-silencing genes that would normally restrain cell growth.
The opposite problem occurs in pediatric brain tumors called diffuse intrinsic pontine gliomas (DIPGs). About 80% of these aggressive tumors carry a mutation in histone H3 itself, replacing lysine 27 with methionine (H3K27M).12Cancer Cell. Histone H3.3K27M Accelerates Spontaneous Diffuse Intrinsic Pontine Glioma and Drives Bivalent Gene Expression in Mice The mutant histone acts as a poison pill: when PRC2 encounters it, the complex is inhibited in a way that persists even after PRC2 dissociates from that stretch of chromatin.13PubMed Central. Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma The global loss of H3K27me3 that follows derepresses bivalent promoters controlling neural development genes, and that disruption of normal developmental silencing drives tumor formation. The effect on H3K27me2 and H3K27me3 is not identical: trimethylation is hit harder and gets confined to narrow regions, while the dimethyl mark, which is enzymatically easier for PRC2 to produce, spreads more broadly than it normally would.14Nature Communications. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis
A third cancer pattern involves complete loss of PRC2 function. Malignant peripheral nerve sheath tumors frequently lose PRC2 components along with the tumor suppressors NF1 and CDKN2A, stripping cells of their ability to maintain repressive H3K27me3 domains altogether.15Cancer Discovery. Loss of PRC2 function promotes MPNST pathogenesis
Weaver Syndrome and EZH2 in Human Development
Outside of cancer, germline mutations in EZH2 cause Weaver syndrome, a rare overgrowth condition. Features include tall stature, advanced bone age, a large head, and widely spaced eyes. Intellectual disability is common, though the severity varies. Only about 40 cases had been documented in the literature when the genetic cause was first identified.16American Journal of Human Genetics. Mutations in EZH2 Cause Weaver Syndrome Case reports describe a pattern of preserved motor milestones alongside delayed cognitive and language development, with limited vocabulary persisting into the toddler years.17PubMed Central. Clinical and genetic characterization of Weaver syndrome: A case report of an EZH2 mutation and review of the literature A child carrying a deletion that removed the entire EZH2 gene showed overlapping features, suggesting that the syndrome results from loss of EZH2 function rather than a toxic gain.18PubMed. The phenotype of EZH2 haploinsufficiency-1.2-Mb deletion at 7q36.1 in a child with tall stature and intellectual disability This is a striking illustration of how precisely calibrated H3K27 methylation needs to be during growth: too much or too little can both cause disease, depending on the tissue.
Immune Cell Decisions
Bivalent chromatin is not exclusive to embryonic stem cells. Naive immune T cells also park repressive H3K27me3 alongside activating H3K4me3 at the promoters of transcription factors essential for mounting an immune response, including Tbx21, Eomes, and Irf4. When a naive T cell encounters a virus-infected cell and begins differentiating into an effector killer cell, most of these bivalent sites lose their H3K27me3 within 24 hours, before the cell even divides. The activating mark remains, and transcription of those key genes ramps up rapidly.19PubMed Central. Mapping histone methylation dynamics during virus-specific CD8+ T cell differentiation in response to infection The resolution of bivalent domains in T cells parallels what happens in embryonic differentiation but occurs on a much faster timescale, reflecting the urgency of an immune response.
Drugs That Target EZH2
The fact that EZH2 is overactive in some cancers made it a natural drug target. Tazemetostat, a small molecule that blocks EZH2’s catalytic activity, became the first approved EZH2 inhibitor. It received approval for two indications: advanced epithelioid sarcoma (a rare soft-tissue cancer that loses the tumor suppressor INI1/SMARCB1, which normally restrains PRC2 activity) and relapsed or refractory follicular lymphoma with EZH2 mutations.20PubMed Central. Tazemetostat: EZH2 Inhibitor In the epithelioid sarcoma trial, about 15% of patients had an objective tumor response, and a quarter maintained disease control at 32 weeks, with a median overall survival of 19 months.21PubMed. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study Those numbers are modest, but for a cancer with few effective treatments, they represented a meaningful advance.
A limitation of catalytic inhibitors like tazemetostat is that they only block the methyltransferase activity of EZH2. In some cancers, EZH2 appears to drive tumor growth through roles that do not depend on its catalytic function, meaning the enzyme’s presence on chromatin matters even when it is not actively adding methyl marks. Researchers have begun developing a different class of drugs called PROTACs that hijack the cell’s protein-disposal system to destroy EZH2 entirely, rather than just blocking its active site. Early-stage compounds have shown the ability to degrade EZH2 and other PRC2 subunits across multiple prostate cancer cell lines, outperforming catalytic inhibitors in that context.22PubMed Central. EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2 Other groups have reported highly potent EZH2 PROTAC degraders designed to suppress both catalytic and non-catalytic oncogenic functions of the protein.23PubMed Central. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2 These are still preclinical, but the strategy highlights how understanding the biology of H3K27 methylation opens doors for therapy design.
Plants Remember Winter Through H3K27me3
H3K27 methylation is not exclusive to animals. In plants, the same Polycomb machinery controls some remarkably elegant biology. The best-known example is vernalization: the process by which a plant “remembers” that it experienced a prolonged cold spell and uses that memory to time its flowering in spring. In Arabidopsis, the key target is a gene called FLC (FLOWERING LOCUS C), which represses flowering. During weeks of cold, a plant-specific version of PRC2 progressively adds H3K27me3 across the FLC gene body, silencing it. Once the cold is over and temperatures rise, that trimethyl mark persists, keeping FLC off so the plant can flower.24PubMed Central. A PHD-polycomb repressive complex 2 triggers the epigenetic silencing of FLC during vernalization
What makes this particularly interesting is the stability of the mark. Even when vernalized plant tissue is taken through the dramatic stress of callus culture and regeneration, meaning cells are dedifferentiated and then coaxed back into forming new plants, the H3K27me3 at FLC is maintained throughout.25PubMed Central. Inheritance of vernalization memory at FLOWERING LOCUS C during plant regeneration The plant’s cold memory survives reprogramming. Stress-responsive genes in plants are also regulated by H3K27me3, making the writers and erasers of this mark central hubs for how plants adapt to changing environments.26PubMed Central. Finding balance: the dynamic interplay between H3K27me3 writers and erasers in regulating environmental plasticity and memory
An Ancient System
PRC2 is not a recent evolutionary invention. The core subunits are found across animals, plants, fungi, and beyond. Phylogenetic surveys have identified PRC2 components in all major eukaryotic supergroups, and putative versions of the catalytic subunit have even been found in Discoba, a lineage thought to be near the root of the eukaryotic tree of life.27Life Science Alliance. Phylogenetic profiling resolves early emergence of PRC2 and illuminates its functional core Across hundreds of species examined, the catalytic subunit and its partner EED/ESC form a conserved functional core, suggesting that the ability to methylate H3K27 arose very early and was important enough to be retained over more than a billion years of evolution.28PubMed Central. Polycomb Repressive Complex 2 in Eukaryotes-An Evolutionary Perspective While the accessory subunits and regulatory inputs have diversified enormously between kingdoms, the basic chemical reaction, adding methyl groups to H3K27, has barely changed.
Aging Blood Vessels and Shifting Methylation
H3K27 methylation does not stay constant across a lifetime. In aging mouse blood vessels, multiple forms of H3K27 methylation decline while acetylation at the same position increases. Out of ten histone marks that changed with age in vascular smooth muscle, seven involved modifications at H3K27, with mono- and dimethylation both dropping in older animals.29Cardiovascular Research. Smooth muscle mineralocorticoid receptor as an epigenetic regulator of vascular ageing Deleting the mineralocorticoid receptor specifically in smooth muscle cells partially protected against this age-related loss, hinting that hormonal signaling through this receptor contributes to the epigenetic drift. Whether similar shifts occur in human vasculature and whether they contribute to age-related vascular stiffness is still being explored, but the sheer concentration of age-related changes at H3K27 is striking. It suggests that the balance between methylation and acetylation at this one residue is a sensitive barometer of cellular aging in at least some tissues.
Measuring H3K27me3 Across the Genome
Researchers have several ways to map where H3K27me3 sits across a cell’s genome, and the choice of technique shapes what they see. The traditional approach, ChIP-seq, involves chemically fixing proteins to DNA, shearing the chromatin, and pulling down fragments bound to H3K27me3 with an antibody. Newer methods called CUT&RUN and CUT&Tag skip the fixation and shearing steps, instead using an antibody-guided enzyme to cut the DNA right at the site of the modification. A systematic comparison found that CUT&RUN preferentially captures broad H3K27me3 domains, while CUT&Tag produces sharper, more localized peaks.30PubMed Central. Comparative analyses of ChIP-seq, CUT&RUN and CUT&Tag for Polycomb chromatin profiling Neither result is “wrong” per se, but they emphasize different features of the same underlying biology. For anyone reading papers about H3K27me3 distributions, it is worth checking which method was used, because broad repressive domains and narrow peaks at promoters can look quite different depending on the assay.